{"title": "Novartis Archives", "author": null, "url": "https://www.europeanpharmaceuticalreview.com/organisations/novartis/", "hostname": "europeanpharmaceuticalreview.com", "description": "News stories and articles referencing Novartis on European Pharmaceutical Review", "sitename": "European Pharmaceutical Review", "date": "2023-08-31", "cleaned_text": "sickle cell disease](https://www.europeanpharmaceuticalreview.com/news/186261/stem-cell-therapy-delivers-potential-for-sickle-cell-disease/) A Novartis' Phase I/II study for sickle cell disease trialling the gene therapy OTQ92 is the first treatment to target a new genetic area and use cryopreserved stem cells, according to new paper "}